On Tuesday, a tiny shred of data on Amgen’s lead obesity candidate — not yet verified — erased $12 billion in market value.

Amgen’s stock fell 7% after an analyst posted a note on MariTide’s influence on bone density which was noticed in a data ...

Analysts cited data from a phase one study showing the highest dose of Amgen’s MariTide was linked to roughly 4% loss of bone ...

Amgen (NASDAQ:AMGN) shares fell in the evening hours on Tuesday after Cantor Fitzgerald argued that a potential loss of bone ...

BioNTech said that it is acquiring the Chinese drugmaker Biotheus for $800 million to bolster its cancer strategy. The two ...

Negative data cost AbbVie billions of dollars in market value and convinced analysts Bristol Myers had placed a better bet in ...

A fourth tab, called “DEXA cohort 9 four,” contains patient-level data for the top MariTide dose. Cantor analyst Olivia ...

The Dow and S&P 500 closed at all-time highs on Monday, with both surpassing key levels as the trading day ended for the ...

Shares in AbbVie slumped Monday after the company disclosed its psychiatric medicine emraclidine didn’t best placebo in two ...

Bank stocks largely boosted the Dow, as investors hope the sector could see weaker regulation in a second Trump ...

Cantor Fitzgerald analyst Olivia Brayer maintained a Hold rating on Gilead Sciences (GILD – Research Report) yesterday and set a price ...

Cantor Fitzgerald analyst Olivia Brayer lowered the firm’s price target on BioMarin (BMRN) to $90 from $110 and keeps an Overweight rating on the shares following the Q3 results. The firm cites ...